BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
Category: #health  By Mateen Dalal  Date: 2019-05-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation

Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailability) and safety study of the company’s product candidate BXCL501. It is a proprietary sublingual thin-film preparation of dexmedetomidine aimed at acute treatment of agitation across several neuropsychiatric indications.

Sources close to the matter informed that administration of BXCL501 in the Phase 1 safety and pharmacokinetic (PK) study successfully achieved targeted exposure levels that were experienced to be therapeutic in previous IV Dex study of the company and for evaluation of efficacy in agitated schizophrenia patients, BTI intends to advance BXCL501 into a Phase 2 study.

The company hopes that the results from the Phase 2 trial would help power a planned Phase 3 pivotal trial.

Apparently, BTI is a clinical-stage biopharmaceutical development company applying new artificial intelligence approaches to recognize and advance next wave of medicines in immuno-oncology and neuroscience.

The IND-opening Phase 1 study was seemingly a double-blinded placebo-controlled, dose-escalation, single-dose study of BXCL501 that had 42 adult volunteers enrolled for several dosing groups. The primary endpoints of the study were safety and PK, while secondary endpoints contained assessment of pharmacodynamics and the relationship between PD endpoints and BXCL501 concentrations.

Sources mentioned that in November 2018, the company had unveiled findings from the study which showed that BXCL501 swiftly achieved targeted exposure levels compatible with the levels observed in the intravenous Dex study in schizophrenia patients. Results from the Phase 1 study also indicated dose-proportional PK consistent with the IV Dex trial along with PD effects lasting 4 to 6 hours, which company believes are clinically favourable features.

According to Chief Executive Officer of BioXcel Therapeutics, (Ph.D.) Vimal Mehta, in Phase 1 study the sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic in the acute treatment of agitation. Besides, the PK profile of sublingual BXCL501 defined proportionality of dose and the potential for a fast onset of action.

Source Credit: http://www.globenewswire.com/news-release/2019/05/20/1827676/0/en/BioXcel-Therapeutics-Achieved-Targeted-Exposures-of-BXCL501-Designed-For-Non-Invasive-Acute-Treatment-of-Agitation-in-Neuropsychiatric-Diseases.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
By Mateen Dalal

Hyundai Motor Company identifies the significance and impact of automobiles, and strives to fulfill its goals by creating new and advanced vehicles that addresses all the vital issues faced by drivers. The automobile giant has effectively become...

TransPerfect expands its portfolio by acquiring Sublime Subtitling
TransPerfect expands its portfolio by acquiring Sublime Subtitling
By Mateen Dalal

With decades of hard work and hands-on experience, TransPerfect has managed to become one of the largest global providers of technology and language solutions for companies worldwide. With over 5,000 global organizations employing its GlobalLink®...

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...